Octagon Capital

  • Harbour BioMed closes Series C financing round

    On July 10, Harbour BioMed announced completion of its Series C financing round of 102.8 million US dollars to accelerate the development of its innovative biopharmaceutical product pipeline targeting cancer, immunologic diseases, and COVID-19.

  • New Horizon Health closes USD30m Series E round

    New Horizon Health, China’s first biotech company to focus on early-stage cancer screening, today announced the completion of a 30 million US dollars Series E financing round, led by Rock Springs Capital, with participation from OrbiMed, Rock Springs Capital, Cormorant Asset Management, CR-CP Life Science Fund, Octagon Capital and existing investor Qiming Venture Partners.